Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Therapeutic procedure Oral Duplicate | Therapeutic procedure Oral Triplicate | Combined Modality Therapy Dose Stable
Item
currently being treated with the following: dual or triple oral therapy - on a stable combination and dose for at least 3 months.
boolean
C0087111 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0205173 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205174 (UMLS CUI [2,3])
C0009429 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Glycosylated hemoglobin A
Item
hba1c between 7.5% and 10.0%.
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
bmi >27.
boolean
C1305855 (UMLS CUI [1])
Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation
Item
receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.
boolean
C0744425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0017712 (UMLS CUI [2])
C0017710 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs
Item
have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.
boolean
C2348568 (UMLS CUI [1])
C0184661 (UMLS CUI [2])
C0087111 (UMLS CUI [3])
C0543467 (UMLS CUI [4])
C0013230 (UMLS CUI [5])
Insulin | Meglitinide | Acarbose | Pharmaceutical Preparations Affecting Gastrointestinal Motility | exenatide | Glucagon-Like Peptide 1 Analogue | Anti-Obesity Agents
Item
treatment with the following medications: *insulin as outpatient therapy within last 3 months; *meglitinides, or acarbose within the last 3 months; *regular use of any drugs that directly affect gastrointestinal motility; *any previous (study) therapy with exenatide or glucagon-like peptide-1 (glp-1) analogue; *anti-obesity agent use within the last 3 months.
boolean
C0021641 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0050393 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0392760 (UMLS CUI [4,2])
C0017184 (UMLS CUI [4,3])
C0167117 (UMLS CUI [5])
C0061355 (UMLS CUI [6,1])
C0243071 (UMLS CUI [6,2])
C0376607 (UMLS CUI [7])
Drugs, Non-Prescription
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])